 |
|
|
| |
Resistance Analysis of Virologic Failures in Hepatitis C Genotype 1-Infected
Patients Treated With Grazoprevir + Elbasvir ± Ribavirin: the C-WORTHY Study
|
| |
| |
Reported by Jules Levin EASL 2015 April 22-26 Vienna Austria
Stuart Black1; Irene Pak1; Paul Ingravallo1; Pat McMonagle1; Robert Chase1; Melissa Shaughnessy1; Peggy Hwang1; Barbara Haber1; P. Richard Harrigan2; Chanson Brumme2; Daria Hazuda1; Anita Y.M. Howe1
1Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA; 2BC Centre for Excellence in HIV/AIDS, University of British Columbia, Vancouver, Canada
MK8408 is a 2nd generation picomolar pangenotypic MS5A inhibitor in development by Merck, and as previously mentioned acquired 2 two nucleotide prodrugs/nuk polymerase inhibitors from Idenix (IDX21437 and IDX21459):
A Phase 1 Study to Evaluate the Interaction of HCV NS5B Inhibitor MK-3682 With HCV NS3/4A Protease Inhibitor MK-5172 and HCV NS5A Inhibitor MK-8408 in Healthy Subjects - (04/23/15)
MK-8408, a Potent and Selective NS5A Inhibitor With a High Genetic Barrier to Resistance and Activity Against HCV Genotypes 1-6......http://www.natap.org/2014/AASLD/AASLD_40.htm
The Combination of Grazoprevir (MK-5172), an NS3 Inhibitor, and MK-8408, an NS5A Inhibitor, Presents a High Genetic Barrier to Resistance in HCV Genotypes 1a and 3a......http://www.natap.org/2014/AASLD/AASLD_56.htm
|
| |
|
|
|
|
|
